You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

A Primer on Oral Selective Estrogen Receptor Degraders in Metastatic Hormone Receptor-Positive Breast Cancer

  • Authors: Erika Hamilton, MD
  • CME / ABIM MOC Released: 3/23/2023
  • Valid for credit through: 3/23/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, obstetricians, gynecologists, and pathologists.

The goal of this activity is for learners to be better able to appreciate the evolution of oral SERDs, clinical trial data, and the key considerations for incorporating oral SERDs into the treatment paradigm for patients with HR-positive breast cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of action of oral SERDs
    • Mutational considerations associated with the implementation of oral SERDs into the treatment paradigm for patients with advanced HR-positive breast cancer
    • Clinical data associated with oral SERDs for estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
  • Demonstrate greater confidence in their ability to
    • Identify the optimal patient to receive an oral SERD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Erika Hamilton, MD

    Director
    Breast Cancer Research Program
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Disclosures

    Erika Hamilton, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Arcus Biosciences; Arvinas, Inc.; AstraZeneca Pharmaceuticals LP; Black Diamond Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; CytomX Therapeutics; Daiichi Sankyo, Inc.; Dantari, Inc.; Deciphera Pharmaceuticals; Eisai Inc.; Genentech; Greenwich LifeSciences; H3 Biomedicine; iTeos; Janssen Biotech, Inc.; Lilly; Loxo Oncology; Merck; Mersana Therapeutics, Inc.; Novartis; Orum Therapeutics; Pfizer Inc.; Propella Therapeutics; Puma Biotechnology; Relay Therapeutics; Roche; Seagen, Inc.; Silverback Therapeutics
    Research funding from: AbbVie Inc.; Acerta Pharma; Accutar Biotechnology; ADC Therapeutics; AKESOBIO, Inc.; Amgen Inc.; Aravive, Inc.; ArQule, Inc.; Artios Pharma Ltd.; Arvinas, Inc.; AstraZeneca Pharmaceuticals LP; AtlasMedx, Inc.; Black Diamond Therapeutics; Bliss BioPharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen, Ltd.; Cullinan-Florentine; Curis, Inc.; CytomX Therapeutics; Daiichi Sankyo, Inc.; Dantari, Inc.; Deciphera Pharmaceuticals; Duality Biologics; eFFECTOR Therapeutics; Ellipses Pharma; Elucida Oncology; EMD Serono; Fochon Biosciences; Fujifilm Pharmaceuticals USA, Inc.; G1 Therapeutics; Genentech; H3 Biomedicine; Harpoon Therapeutics; Hutchinson MediPharma; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte Corporation; Infinity Pharmaceuticals; InventisBio; Jacobio Pharmaceuticals Group, Co., Ltd.; Karyopharm Therapeutics; Leap Therapeutics; Lilly; Lycera Corporation; Mabspace Biosciences; Macrogenics, Inc.; MedImmune Inc.; Merck; Mersana Therapeutics, Inc.; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates; Myriad Genetic Laboratories; Novartis; Nucana plc; Olema Pharmaceuticals; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; ORIC Pharmaceuticals; Orinove, Inc.; Pfizer Inc.; PharmaMar; Pieris Pharmaceuticals; Pinoyr Immunotherapeutics; Plexxikon Inc.; Radius Health, Inc.; Regeneron Pharmaceuticals, Inc.; Relay Therapeutics; Repertoire Immune Medicine; Rgenix; Roche; Seagen, Inc.; Sermonix Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; StemCentRx, Inc.; Sutro Biopharma, Inc.; Syndax Pharmaceuticals, Inc.; Syros Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.; TapImmune, Inc.; TESARO, Inc.; Tolmar, Inc.; Torque Therapeutics; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; Zenith Epigenetics; Zymeworks, Inc.

Editor

  • Vickie Phoenix, BS

    Medical Education Director, Medscape, LLC 

    Disclosures

    Vickie Phoenix, BS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

A Primer on Oral Selective Estrogen Receptor Degraders in Metastatic Hormone Receptor-Positive Breast Cancer

Authors: Erika Hamilton, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/23/2023

Valid for credit through: 3/23/2024

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to appreciate the evolution of oral SERDs, clinical trial data, and the key considerations for incorporating oral SERDs into the treatment paradigm for patients with HR-positive breast cancer.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print